Literature DB >> 26842234

Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.

Edward J Hartsough1, Andrew E Aplin2.   

Abstract

Targeted therapies have advanced the treatment options for cutaneous melanoma, but many patients will progress on drug. Patient-derived xenografts (PDX) can be used to recapitulate therapy-resistant tumors. Furthermore, PDX modeling can be utilized in combination with targeted sequencing and phosphoproteomic platforms, providing preclinical basis for second-line targeted inhibitor strategies. See related article by Krepler et al., p. 1592. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2016        PMID： 26842234      PMCID： PMC4818736          DOI： 10.1158/1078-0432.CCR-15-3054

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  13 in total

1.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.

Authors:  Yoko S DeRose; Guoying Wang; Yi-Chun Lin; Philip S Bernard; Saundra S Buys; Mark T W Ebbert; Rachel Factor; Cindy Matsen; Brett A Milash; Edward Nelson; Leigh Neumayer; R Lor Randall; Inge J Stijleman; Bryan E Welm; Alana L Welm
Journal:  Nat Med       Date:  2011-10-23       Impact factor: 53.440

2.  In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors.

Authors:  Kevin J Basile; Ethan V Abel; Neda Dadpey; Edward J Hartsough; Paolo Fortina; Andrew E Aplin
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

3.  The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

Authors:  Matthew M K Chan; Lauren E Haydu; Alexander M Menzies; Mary W F Azer; Oliver Klein; Megan Lyle; Arthur Clements; Alexander Guminski; Richard F Kefford; Georgina V Long
Journal:  Cancer       Date:  2014-07-01       Impact factor: 6.860

Review 4.  Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.

Authors:  Andrea Ladányi
Journal:  Pigment Cell Melanoma Res       Date:  2015-04-20       Impact factor: 4.693

5.  Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.

Authors:  Zachary A Cooper; Vikram R Juneja; Peter T Sage; Dennie T Frederick; Adriano Piris; Devarati Mitra; Jennifer A Lo; F Stephen Hodi; Gordon J Freeman; Marcus W Bosenberg; Martin McMahon; Keith T Flaherty; David E Fisher; Arlene H Sharpe; Jennifer A Wargo
Journal:  Cancer Immunol Res       Date:  2014-04-29       Impact factor: 11.151

6.  Comparison of human cord blood engraftment between immunocompromised mouse strains.

Authors:  Sean P McDermott; Kolja Eppert; Eric R Lechman; Monica Doedens; John E Dick
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

7.  Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.

Authors:  Edward J Hartsough; Kevin J Basile; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2014-02-11       Impact factor: 5.852

8.  AKT1 Activation Promotes Development of Melanoma Metastases.

Authors:  Joseph H Cho; James P Robinson; Rowan A Arave; William J Burnett; David A Kircher; Guo Chen; Michael A Davies; Allie H Grossmann; Matthew W VanBrocklin; Martin McMahon; Sheri L Holmen
Journal:  Cell Rep       Date:  2015-10-22       Impact factor: 9.423

9.  Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.

Authors:  Clemens Krepler; Min Xiao; Katrin Sproesser; Patricia A Brafford; Batool Shannan; Marilda Beqiri; Qin Liu; Wei Xu; Bradley Garman; Katherine L Nathanson; Xiaowei Xu; Giorgos C Karakousis; Gordon B Mills; Yiling Lu; Tamer A Ahmed; Poulikos I Poulikakos; Giordano Caponigro; Markus Boehm; Malte Peters; Lynn M Schuchter; Ashani T Weeraratna; Meenhard Herlyn
Journal:  Clin Cancer Res       Date:  2015-12-16       Impact factor: 12.531

10.  Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases.

Authors:  Heike Seifert; Eishu Hirata; Martin Gore; Komel Khabra; Christina Messiou; James Larkin; Erik Sahai
Journal:  Pigment Cell Melanoma Res       Date:  2015-11-03       Impact factor: 4.693
View more
  5 in total

1.  Biodynamic digital holography of chemoresistance in a pre-clinical trial of canine B-cell lymphoma.

Authors:  Honggu Choi; Zhe Li; Hao Sun; Dan Merrill; John Turek; Michael Childress; David Nolte
Journal:  Biomed Opt Express       Date:  2018-04-17       Impact factor: 3.732

2.  Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.

Authors:  Francesca Ricci; Federica Guffanti; Giovanna Damia; Massimo Broggini
Journal:  Mol Cancer       Date:  2017-05-30       Impact factor: 27.401

Review 3.  Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.

Authors:  Giuseppina Barutello; Valeria Rolih; Maddalena Arigoni; Lidia Tarone; Laura Conti; Elena Quaglino; Paolo Buracco; Federica Cavallo; Federica Riccardo
Journal:  Int J Mol Sci       Date:  2018-03-10       Impact factor: 5.923

Review 4.  The MeLiM Minipig: An Original Spontaneous Model to Explore Cutaneous Melanoma Genetic Basis.

Authors:  Emmanuelle Bourneuf
Journal:  Front Genet       Date:  2017-10-13       Impact factor: 4.599

Review 5.  Cutaneous Melanoma-A Long Road from Experimental Models to Clinical Outcome: A Review.

Authors:  Dorina Coricovac; Cristina Dehelean; Elena-Alina Moaca; Iulia Pinzaru; Tiberiu Bratu; Dan Navolan; Ovidiu Boruga
Journal:  Int J Mol Sci       Date:  2018-05-24       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.